ConductScience.org, home

Paper14565784

Dutasteride.

Evans HC and 1 other. Drugs Aging, 2003. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. Dutasteride. Papers, record 14565784. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/14565784

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dutasteride.
PubMed
Journal
Drugs Aging
PubMed
Year
2003
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
1.15
iCite
Revised in PubMed
2018-11-13
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Evans HCHannah C
2Goa KLKaren L

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
5-alpha Reductase InhibitorsMajor topic
AzasteroidsMajor topic
Prostatic HyperplasiaMajor topic
Drug Therapy, Combination
Dutasteride
Humans
Male
Prostate-Specific Antigen
Randomized Controlled Trials as Topic

Source PubMed

Download CSV of topics

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17577933Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.Biochemistry1995https://conductscience.org/library/papers/7577933PubMed
212814679Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.Eur Urol2003https://conductscience.org/library/papers/12814679PubMed
39143856Benign prostatic hyperplasia. Practical treatment guidelines.Drugs Aging1997https://conductscience.org/library/papers/9143856PubMed
49061268Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.Drugs Aging1997https://conductscience.org/library/papers/9061268PubMed
510235693Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.Drugs1999https://conductscience.org/library/papers/10235693PubMed
69871428A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.Clin Pharmacol Ther1998https://conductscience.org/library/papers/9871428PubMed
79760689Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase.Pharm Biotechnol1998https://conductscience.org/library/papers/9760689PubMed
812887480Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.BJU Int2003https://conductscience.org/library/papers/12887480PubMed
99316864Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.J Pharmacol Exp Ther1997https://conductscience.org/library/papers/9316864PubMed
1010073740The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.Br J Clin Pharmacol1999https://conductscience.org/library/papers/10073740PubMed
1112350480Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.Urology2002https://conductscience.org/library/papers/12350480PubMed
129951948Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.Drugs1999https://conductscience.org/library/papers/9951948PubMed
1315126539Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.J Clin Endocrinol Metab2004https://conductscience.org/library/papers/15126539PubMed

Download CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
41405174Impact of Administration Time Errors on Clearance Estimation in Pharmacokinetic Analyses.Clin Transl Sci2025https://conductscience.org/library/papers/41405174PubMed
40114308Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters.Clin Exp Reprod Med2025https://conductscience.org/library/papers/40114308PubMed
39091900Enhancing hair regeneration: Recent progress in tailoring nanostructured lipid carriers through surface modification strategies.ADMET DMPK2024https://conductscience.org/library/papers/39091900PubMed
38243983Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review.Curr Med Chem2024https://conductscience.org/library/papers/38243983PubMed
32742388Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials.Exp Ther Med2020https://conductscience.org/library/papers/32742388PubMed
30871552Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.BMC Urol2019https://conductscience.org/library/papers/30871552PubMed
30367429Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride.Clin Drug Investig2019https://conductscience.org/library/papers/30367429PubMed
29379733The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.Asian J Urol2018https://conductscience.org/library/papers/29379733PubMed
29153901Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.Pract Radiat Oncol2018https://conductscience.org/library/papers/29153901PubMed
27364517Impact of Formulation on the Pharmacokinetic Profile of Dutasteride.Clin Drug Investig2016https://conductscience.org/library/papers/27364517PubMed
25984604Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system.Int J Mol Sci2015https://conductscience.org/library/papers/25984604PubMed
25753982
Patients with Persistently Elevated PSA and Negative Results of TRUS-Biopsy: Does 6-Month Treatment with Dutasteride can Indicate Candidates for Re-Biopsy. What is the Best of Saturation Schemes: Transrectal or Transperineal Approach?
Pathol Oncol Res2015https://conductscience.org/library/papers/25753982PubMed
24872577Relative adrenal insufficiency in mice deficient in 5α-reductase 1.J Endocrinol2014https://conductscience.org/library/papers/24872577PubMed
23737668Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures.Int J Nanomedicine2013https://conductscience.org/library/papers/23737668PubMed
21629218Targeting 5α-reductase for prostate cancer prevention and treatment.Nat Rev Urol2011https://conductscience.org/library/papers/21629218PubMed
190300205alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.Prostate Cancer Prostatic Dis2009https://conductscience.org/library/papers/19030020PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/14565784

GET https://conductscience.org/api/papers/v1/14565784/authors